Does side branch dilation with a sirolimus-coated balloon provide non-inferior outcomes compared to a paclitaxel-coated balloon in patients with de novo non-left main coronary bifurcation lesions?
Sirolimus-coated balloons are non-inferior to paclitaxel-coated balloons for side branch dilation in the treatment of de novo non-left main coronary bifurcation lesions.
In de novo non-left main CBL treatment, MV stenting accompanied by SB dilation with the sirolimus DCB was non-inferior to the paclitaxel DCB.
Zhou et al. (Sat,) studied this question.